Abstract
We have studied a family (12 members) with 3 patients (2 adult females and 1 pubertal-aged genotypic male) affected by congenital adrenal hyperplasia due to 17-α-hydroxylase deficiency, all of whom presented as phenotypically female subjects with lack of sexual development and with hypokalemic hypertension. The baseline hormonal pattern revealed low glucocorticoid levels (17-hydroxyprogesterone, plasma and urinary cortisol, cortisol secretion rate), as well as androgen (testosterone and dehydroepiandrosterone sulfate) and estrogen (17-ß-estradiol) levels, since the defect is present at both adrenal and gonadal levels. As a consequence ACTH, LH, and FSH concentrations were high. Otherwise steroids not requiring 17-α-hydroxylation, such as deoxycorticosterone, corticosterone and their 18-hydroxylated compounds, were secreted in excess with the exception of aldosterone whose levels were undetectable; baseline plasma renin activity levels were suppressed. Short-term dexamethasone treatment normalized potassium and reduced blood pressure and the abnormal mineralocorticoid levels. During chronic ACTH suppression with low doses of glucocorticoids (8 years), electrolyte disturbances were corrected, blood pressure was normalized in 2 cases but only reduced in the third; plasma renin activity returned to normal range within four years in all the patients, while urinary aldosterone was normalized only after 8 years of therapy and became partially responsive to posture, ACTH, angiotensin II, and furosemide. The other mineralo-corticoids were reduced but remained above the normal range. The HLA-genotyping in all the family members revealed that the gene responsible for 17-α-hydroxylase deficiency was not linked to the HLA system. Measurement of plasma steroids (deoxycorticosterone, corticosterone, aldosterone) in this family revealed that the heterozygotes were different from the control population only in their ACTH-stimulated corticosterone levels.
Similar content being viewed by others
References
Biglieri E.G., Herron H.A., Brust N. 17-α-hydroxylation in man. J. Clin. Invest. 45: 1946, 1966.
Mills I.H., Wilson R.J., Tait A.D., Cooper H.R. Steroid metabolic studies in a patient with 17-α-hydroxylation deficiency. J.Endocrinol. 38: 19, 1967.
Goldsmith O., Solomon D.H., Horton R. Hypogonadism and mineralocorticoid excess. The 17-hydroxylase deficiency syndrome. N. Engl. J. Med. 277: 673, 1967.
Rovner D.R., Conn J.W., Cohen E.L., Berlinger F.G., Kern D.C. Biglieri’s syndrome: unexplained by 17-α-hydroxylase defect alone. J. Lab. Clin. Med. 72: 1009, 1968.
Mallin S.R. Congenital adrenal hyperplasia secondary to 17-hydroxylase deficiency. Ann. Intern. Med. 49: 1930, 1969.
Linquette M., Dupont A., Rocadot A., Lefebvre J., May J.P., Cappoen J.P. Deficit en 17-hydroxylase. A propos d’une observation. Ann. Endocrinol. 32: 574, 1971.
De Lange W.E., Weeke A., Artz W., Jansen W., Doorenbos H. Primary amenorrhea with hypertension due to 17-hydroxylase deficiency. Acta. Med. Scand. 193: 565, 1973.
Rovner D.R., Conn J.W., Cohen E.L., Berlinger F.G., Kern D.C., Gordon D.L. 17-α-hydroxylase deficiency. A combination of hydroxylation defect and reversible blockade in aldosterone biosynthesis. Acta Endocrinol. (Copenh.) 90: 490, 1979.
Saruta T., Kondo K., Saito I., Nagahomo S., Suzuki H., Konishi K., Matsuki S. Control of aldosterone in 17-α-hydroxylase deficiency. Horm. Res. 13: 98, 1980.
Tvedegaard E., Frederiksen V., Olgaard K., Damkjaer Nielsen M., Starup J. Two cases of 17-α-hydroxylase deficiency. One combined with complete gonadal agenesis. Acta Endocrinol. (Copenh.) 98: 267, 1981.
D’Armiento M., Reda G., Kater C., Shackleton C.H.L., Biglieri E.G. 17-α-hydroxylase deficiency: mineralocorticoid hormone profiles in an affected family. J. Clin. Endocrinol. Metab. 56: 697, 1983.
New M.I. Male pseudohermaphroditism due to 17-α-hydroxylase deficiency. J. Clin. Invest. 49: 1930, 1970.
Mantero F., Busnardo B., Riondel A., Veyrat R., Austoni M. Hypertension arterielle, alcalose hypokaliemique et pseudohermaphrodisme male par deficit en 17-α-hydroxylase. Schweiz. Med. Wochenschr. 101: 38, 1971.
Bricaire H., Luton J.P., Laudat P., Legrand J.P., Turpin G., Corvol P., Lemmer M. A new male pseudohermaphroditism associated with hypertension due to a block of 17-α-hydroxylation. J. Clin. Endocrinol. Metab. 35: 67, 1972.
Hammerstein J., Zielska F., Distler A., Wolff H.P. 17-α-hydroxylase deficiency of the gonads and adrenals in a male pseudohermaphrodite. Acta Endocrinol. (Copenh.) 173 (Suppl.): 76, 1973.
Alvarez M.N., Coutier M.D., Hayles A.B. Male pseudohermaphroditism due to 17-hydroxylase deficiency in 2 siblings. Pediatr. Res. 7: 325, 1973.
Kershnar A.K., Borut D., Kogut M.D., Biglieri E.G., Schambelan M. Studies in a phenotypic female with 17-a -hydroxylase deficiency. J. Pediatr. 89: 395, 1976.
Tournaire J., Audi Parera L., Loras B., Blum J., Castelnovo P., Forest M.G. Male pseudohermaphroditism with hypertension due to 17-α-hydroxylation deficiency. Clin. Endocrinol. (Oxf.) 5: 53, 1976.
Waldhause W., Herkner K., Novotry P., Bratusch-Marrain P. Combined 17-α- and 18-α-hydroxylase deficiency associated with complete male, pseudohermaphroditism and hypoaldosteronism. J. Clin. Endocrinol. Metab. 46: 236, 1978.
Dupont B., Oberfield S.E., Smithwick E.M., Lee T.D., Levine L.S. Close genetic linkage between HLA and congenital adrenal hyperplasia (21-hydroxylase deficiency) Lancet 2: 1309, 1977.
Terasaky P.I., McClelland J.D. Microdroplet assay to human cytotoxins. Nature 204: 998, 1964.
Boscaro M., Karbowiak I., Mantero F. Urinary free cortisol radioimmunoassay; its application in the diagnosis of adrenal diseases. Ric. Clin. Lab. 8: 169, 1978.
Boscaro M., Armanini D., Mantero F. Indicazioni allo studio della funzione surrenalica mediante misura del tasso di secrezione del cortisolo. Quaderni Sclavo di Diagnostica 12: 39, 1976.
Carpenè G., Opocher G., Vettoretti A., Rocco S., Scarante M., Mantero F. Impact of high-performance liquid chromatography on the assay of steroid hormones. Ann. N.Y. Acad. Sci., 595: 480, 1990.
Feit J.P., David L., Paticot M.C., Macabeo V., Lebacq E., Francois R. Le deficit en 17-hydroxylase: une cause de croissance et puberté rétardées chez la fille. Arch. Pediatr. 35: 395, 1978.
Kater G.E., Biglieri E.G., Brust N., Chang B., Hirai J. Zona fasciculata origin of 18-hydroxycorticosterone in the chronically suppressed zona glomerulosa. J. Clin. Endocrinol. Metab. 55: 628, 1982.
Scaroni C., Opocher G., Mantero F. Renin-angiotensin-aldosterone system: a long-term follow-up study in 17-α-hydroxylase deficiency syndrome. bl]ReferencesClin. Exp. Hyper. Tens. A8(4–5): 773, 1986.
Rovner D.R., Conn J.W., Cohen E.L., Berlinger F.G., Kern D.C., Gordon DL. 17-α-hydroxylase deficiency. A combination of hydroxylation defect and reversible blockade in aldosterone biosynthesis. Acta Endocrinol. (Copenh.) 90: 490, 1979.
Lorenzen F., Pang S., New M.I., Pollack M., Oberfield S., Dupont B., Chow D., Schneider B., Levine L. Studies of C-21 and C-19 steroids and HLA genotyping in siblings and parents of patients with congenital adrenal hypereplasia due to 21 hydroxylase deficiency. J. Clin. Endocrinol. Metab. 50: 572, 1980.
Mantero F., Scaroni C., Venturi-Pasini C., Fagiolo U. No linkage between HLA and congenital adrenal hyperplasia due to 17-hydroxylase deficiency. N. Engl. J. Med. 303: 530, 1980.
White P.C., New M.I., Dupont B.O. Congenital adrenal hyperplasia. N. Engl. J. Med. 316: 1519, 1987.
Mantero F., Scaroni C., Masarotto P., Venturi-Pasini C. HLA and congenital adrenal hyperplasia. Eur. J. Clin. Invest. 11: 20, 1981.
Simpson E.R., Kagimoto M., Mason J.I., Waterman M.R. Regulation of expression of genes encoding steroidogenic enzymes. In: Mantero F., Takeda R., Scoggins B.A., Biglieri E.G., Funder J.W.(Eds.), The Adrenal and hypertension: from Cloning to Clinic. Serono Symposia Publication, vol. 5, Raven Press, 1989, p.15.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Scaroni, C., Biason, A., Carpenè, G. et al. 17-α-hydroxylase deficiency in three siblings: short- and long-term studies. J Endocrinol Invest 14, 99–108 (1991). https://doi.org/10.1007/BF03350278
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03350278